Abstract
Non-specific inflammatory bowel diseases (IBD) include Crohn’s disease (CD) and ulcerative colitis (UC). Both diseases are characterized by chronic inflammation of unclear etiology. The inflammatory bowel diseases incidence is continuously observed to rise. Colon inflammatory response is a physiological process which occurrence is indispensable as an organisms’ defense reaction. The inflammation may be caused by internal factors associated with body’s cells as well as external factors, such as infections and exposition for inflammatory agents. Until recently, IBD have been classified as autoimmune diseases, today they seem to be associated with gut barrier disorders or dysbiosis. Factors that predispose to inflammatory bowel diseases include: genetic factors, dysbiosis and so called western-type diet, natural components such as gluten and lactose. In addition, the development of the disease is favored by: cigarette smoking, phosphate, nanomolecules, sodium chloride, emulgents, carrageenan, carboxymethylcellulose, pollution, maltodextrin. IBD affects whole the body, causing serious medical consequences. Symptoms like anxiety and chronic stress, that occur commonly, can lead to depressive disorders. Quantitative and qualitative dietary deficiency caused by absorption disorders, may promote the occurrence of osteoporosis and osteopenia. In addition, dysbiosis coexisting with alterations in intestinal permeability can lead to the development of nonalcoholic fatty liver disease. IBD medical consequences include also systemic complications, associated with the extra gastrointestinal manifestations’ occurrence.
References
1. Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn’s and colitis epidemiology study. Gastroenterology 2013;145:158-65.10.1053/j.gastro.2013.04.007Search in Google Scholar PubMed
2. Gearry RB, Richardson A, Frampton CMA, Collett JA, Burt MJ, Chapman BA, et al. High incidence of Crohn’s disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis 2006;12:936-43.10.1097/01.mib.0000231572.88806.b9Search in Google Scholar PubMed
3. Wilson J, Hair C, Knight R, Catto-Smith A, Bell S, Kamm M, et al. High incidence of inflammatory bowel disease in Australia: a prospective population-based Australian incidence study. Inflamm Bowel Dis 2010;16:1550-6.10.1002/ibd.21209Search in Google Scholar PubMed
4. Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T. Prevalence of ulcerative colitis and Crohn’s disease in Japan. J Gastroenterol 2009;44:659-65.10.1007/s00535-009-0057-3Search in Google Scholar PubMed
5. Burisch J., Jess T, Martinato M., Lakatos PL; ECCO -EpiCom.: The burden of inflammatory bowel disease in Europe. J Crohns Colitis, 2013;7(4):322-37.10.1016/j.crohns.2013.01.010Search in Google Scholar PubMed
6. Jakubowski A, Bartnik W, Kraszewska E i wsp. Trendy hospitalizacji z powodu nieswoistych chorob zapalnych jelit w Polsce. Gastroenterologia Polska 2010; 17: 50.Search in Google Scholar
7. Wehkamp J., Gotz M., Herrlinger K., Steurer W., Stange E.: Inflammatory Bowel Disease. Crohn’s disease and ulcerative colitis. Dtsch Arztebl Int., 2016; 113(5): 72-82.Search in Google Scholar
8. Nasef N.A., Mehta S., Ferguson L.R.: Susceptibility to chronic inflammation: an update. Arch Toxicol. 2017 Mar;91(3):1131-1141.10.1007/s00204-016-1914-5Search in Google Scholar PubMed
9. Javed, Q.: Clinical Implications of Tumor Necrosis Factor-Alpha, Interleukin-6 and Resistin in Coronary Artery Disease. World Journal of Cardiovascular Diseases, 2014; 4: 416-42110.4236/wjcd.2014.49052Search in Google Scholar
10. Kaźmierczak E., Jabłecka A.: Zapalne czynniki predykcyjne choroby wieńcowej. Nadciśnienie tętnicze, 2009;12:4.Search in Google Scholar
11. Sudoł-Szopińska I., Kontny E., Maśliński W., Prochorec-Sobieszek M., Kwiatkowska B., i wsp.: Patogeneza reumatoidalnego zapalenia stawow w badaniach radiologicznych. Część I: Powstawanie naciekow zapalnych w błonie maziowej. Journal of Ultrasonography 2012; 12: 202-213Search in Google Scholar
12. Grotesky T., Dirisina R., Sinh P., Mittal N., Managlia E., Williams D., Posca D., Ryu H., Katzman R., Barrett T.:p53 Mediates TNFInduced Epithelial Cell Apoptosis in IBD. The American Journal of Pathology .2012; 181(4): 1306-131510.1016/j.ajpath.2012.06.016Search in Google Scholar PubMed PubMed Central
13. Alhassan Mohammed H., Mirshafiey A., Vahedi H., Hemmasi G., Moussavi Nasl Khameneh A., Parastouei K., et all: Immunoregulation of Inflammatory and Inhibitory Cytokines by Vitamin D3 in Patients with Inflammatory Bowel Diseases. Scand J Immunol. 2017 Jun;85(6):386-394.10.1111/sji.12547Search in Google Scholar PubMed
14. Cătană C.S., Berindan Neagoe I., Cozma V., Magdaş C., Tăbăran F., Dumitraşcu D.L.: Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2015 May 21;21(19):5823-30.10.3748/wjg.v21.i19.5823Search in Google Scholar PubMed PubMed Central
15. Ko W.K., Lee S.H., Kim S.J., Jo M.J., Kumar H., Han I.B., et all: Anti-inflammatory effects of ursodeoxycholic acid by lipopolysaccharide-stimulated inflammatory responses in RAW 264.7 macrophages. PLoS One. 2017; 12(6): e0180673.10.1371/journal.pone.0180673Search in Google Scholar PubMed PubMed Central
16. Allam-Ndoul B., Guenard F., Barbier O., Vohl M.C.: Effect of n-3 fatty acids on the expression of inflammatory genes in THP-1 macrophages. Lipids Health Dis. 2016; 15: 69.10.1186/s12944-016-0241-4Search in Google Scholar PubMed PubMed Central
17. Molfino A., Amabile M.I., Monti M., Muscaritoli M.: Omega-3 Polyunsaturated Fatty Acids in Critical Illness: Anti- Inflammatory, Proresolving, or Both? Oxid Med Cell Longev. 2017; 2017: 5987082.Search in Google Scholar
18. Scaioli E., Liverani E., Belluzzi A.: The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A Comprehensive Review and Future Therapeutic Perspectives. Int J Mol Sci., 2017; 18(12): 2619.Search in Google Scholar
19. Rodriguez-Lagunas M., Ferrer R., Moreno J: Effect of eicosapentaenoic acid-derived prostaglandin E3 on intestinal epithelial barrier function. Prostaglandins Leukot Essent Fatty Acids., 2013;88(5):339-45.Search in Google Scholar
20. Zatorski H., Sałaga M., Zielińska M., Fichna J.: Czynniki genetyczne w patogenezie, przebiegu i leczeniu nieswoistych chorob zapalnych jelit. Postępy Hig Med., 2015;69:335-344.Search in Google Scholar
21. Wejman J., Bartnik W.: Atlas kliniczno-patologiczny nieswoistych chorob zapalnych jelit. Wyd. 1. Poznań: Wydaw: Termedia; 2011. ISBN: 978-83-62138-62-3.Search in Google Scholar
22. de Lange KM., Barrett JC.: Understanding inflammatory bowel disease via immunogenetics. J Autoimmun. 2015 Nov;64:91-100.10.1016/j.jaut.2015.07.013Search in Google Scholar PubMed
23. Konturek S.J., red.: Gastroenterologia i hepatologia kliniczna. Warszawa: Wydaw. Lekarskie PZWL;2006. ISBN 83-200-3188-5.Search in Google Scholar
24. Lauro M.L., Burch J.M., Grimes C.L.: The Effect of NOD2 on the Microbiota in Crohn’s Disease. Curr Opin Biotechnol. 2016 Aug; 40: 97-102.10.1016/j.copbio.2016.02.028Search in Google Scholar PubMed PubMed Central
25. Zhang YZ., Li YY.: Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014 Jan 7;20(1):91-9.10.3748/wjg.v20.i1.91Search in Google Scholar PubMed PubMed Central
26. Iida T., Onodera K., Nakase H.: Role of autophagy in the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2017 Mar 21; 23(11): 1944-1953.10.3748/wjg.v23.i11.1944Search in Google Scholar PubMed PubMed Central
27. Uhlig HH., Muise AM.: Clinical Genomics in Inflammatory Bowel Disease. Trends Genet. 2017 Sep;33(9):629-641.10.1016/j.tig.2017.06.008Search in Google Scholar PubMed
28. Rosen M., MSCI, Dhawan A., MBBS, MSPH, Saeed S.: Inflammatory Bowel Disease in Children and Adolescents. JAMA Pediatr., 2015; 169(11): 1053-1060.Search in Google Scholar
29. Bernstein C.N.: Review article: changes in the epidemiology of inflammatory bowel disease-clues for aetiology. Aliment Pharmacol Ther. 2017 Nov;46(10):911-919.10.1111/apt.14338Search in Google Scholar PubMed
30. Brusaferroa A., Cavallia E., Farinellia E., Cozzalia R., Principib N., Esposito S.: Gut dysbiosis and paediatric Crohn’s disease. J Infect. 2018 Oct 15. pii: S0163-4453(18)30308-6.Search in Google Scholar
31. Lewis JD., Chen EZ., Baldassano R.N., Otley A.R., Griffiths A.M., Lee D., et all: Inflammation, Antibiotics, and Diet as Environmental Stressors of the Gut Microbiome in Pediatric Crohn’s Disease. Cell Host Microbe. 2015 Oct 14;18(4):489-500.10.1016/j.chom.2015.09.008Search in Google Scholar PubMed PubMed Central
32. Khan S., Imran A., Malik A., Chaudhary AA., Rub A., et all: Bacterial imbalance and gut pathologies: Association and contribution of E. coli in inflammatory bowel disease. Crit Rev Clin Lab Sci. 2018 Oct 29:1-1710.1080/10408363.2018.1517144Search in Google Scholar PubMed
33. Tawfik A., Flanagan P.K., Campbell B.J.: Escherichia coli-host macrophage interactions in the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2014 Jul 21; 20(27): 8751-8763.Search in Google Scholar
34. Vrakas S., Mountzouris K.C., Michalopoulos G., Karamanolis G., Papatheodoridis G., Tzathas C., et all: Intestinal Bacteria Composition and Translocation of Bacteria in Inflammatory Bowel Disease. PLoS One. 2017; 12(1): e0170034.10.1371/journal.pone.0170034Search in Google Scholar PubMed PubMed Central
35. Abegunde AT., Muhammad BH., Bhatti O., Ali T.: Environmental risk factors for inflammatory bowel diseases: Evidence based literature review. World J Gastroenterol. 2016 Jul 21; 22(27): 6296-6317.10.3748/wjg.v22.i27.6296Search in Google Scholar PubMed PubMed Central
36. Higuchi LM., Khalili H., Chan AT., Richter JM., Bousvaros A., Fuchs CS.: A Prospective Study of Cigarette Smoking and the Risk of Inflammatory Bowel Disease in Women. Am J Gastroenterol. 2012 Sep; 107(9): 1399-1406.10.1038/ajg.2012.196Search in Google Scholar PubMed PubMed Central
37. Cosnes J.: Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol. 2004 Jun;18(3):481-96.10.1016/j.bpg.2003.12.003Search in Google Scholar PubMed
38. Pineton de Chambrun G., Body-Malapel M., Frey-Wagner I., Djouina M., Deknuydt F., Atrott K., et all: Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in mice. Mucosal Immunol. 2014 May;7(3):589-601.10.1038/mi.2013.78Search in Google Scholar PubMed PubMed Central
39. Dixon LJ., Kabi A., Nickerson KP., McDonald C.: Combinatorial effects of diet and genetics on inflammatory bowel disease pathogenesis. Inflamm Bowel Dis. 2015 Apr;21(4):912-22.10.1097/MIB.0000000000000289Search in Google Scholar PubMed PubMed Central
40. Dolan KT., Chang EB.: Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases. Mol Nutr Food Res. 2017 Jan;61(1).10.1002/mnfr.201600129Search in Google Scholar PubMed PubMed Central
41. Martinez-Medina M., Denizot J., Dreux N., Robin F., Billard E., Bonnet R., et all: Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut. 2014 Jan;63(1):116-24.10.1136/gutjnl-2012-304119Search in Google Scholar PubMed
42. Agus A., Denizot J., Thevenot J., Martinez-Medina M., Massier S., Sauvanet P.: Western diet induces a shift in microbiota composition enhancing susceptibility to Adherent-Invasive E. coli infection and intestinal inflammation. Sci Rep. 2016 Jan 8;6:19032.10.1038/srep19032Search in Google Scholar PubMed PubMed Central
43. Tubbs AL., Liu B., Rogers TD., Sartor RB., Miao EA.: Dietary Salt Exacerbates Experimental Colitis. J Immunol. 2017 Aug 1;199(3):1051-1059.10.4049/jimmunol.1700356Search in Google Scholar PubMed PubMed Central
44. Schatz V., Neubert P., Schroder A., Binger K., Gebhard M., Muller DN., et all: Elementary immunology: Na+ as a regulator of immunity. Pediatr Nephrol. 2017 Feb;32(2):201-210.10.1007/s00467-016-3349-xSearch in Google Scholar PubMed PubMed Central
45. Wu C., Yosef N., Thalhamer T., Zhu C., Xiao S., Kishi Y., et all: Induction of pathogenic Th17 cells by inducible salt sensing kinase SGK1. Nature. 2013 Apr 25; 496(7446): 513-517.10.1038/nature11984Search in Google Scholar PubMed PubMed Central
46. Biesiekierski JR.: What is gluten? J Gastroenterol Hepatol. 2017 Mar;32 Suppl 1:78-81.10.1111/jgh.13703Search in Google Scholar PubMed
47. Herfarth HH., Martin CF., Sandler RS., Kappelman MD., Long MD.: Prevalence of a gluten-free diet and improvement of clinical symptoms in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2014 Jul;20(7):1194-7.10.1097/MIB.0000000000000077Search in Google Scholar PubMed PubMed Central
48. Limketkai BN., Sepulveda R., Hing T., Shah ND., Choe M., Limsui D., Shah S.: Prevalence and factors associated with gluten sensitivity in inflammatory bowel disease. Scand J Gastroenterol. 2018 Feb;53(2):147-151.10.1080/00365521.2017.1409364Search in Google Scholar PubMed
49. Molberg O, Uhlen AK, Jensen T, Flaete NS, Fleckenstein B, Arentz- Hansen H, Raki M, Lundin KE, Sollid LM. Mapping of gluten T-cell epitopes in the bread wheat ancestors: implications for celiac disease. Gastroenterology. 2005;128(2):393-401.10.1053/j.gastro.2004.11.003Search in Google Scholar PubMed
50. Laatikainen R, Koskenpato J, Hongisto SM, Loponen J Poussa T, Huang X, Sontag-Strohm T, Salmenkari H, Korpela R. Pilot Study: Comparison of Sourdough Wheat Bread and Yeast- Fermented Wheat Bread in Individuals with Wheat Sensitivity and Irritable Bowel Syndrome. Nutrients. 2017;9(11).10.3390/nu9111215Search in Google Scholar PubMed PubMed Central
51. Deng Y., Misselwitz B., Dai N., Fox M.: Lactose Intolerance in Adults: Biological Mechanism and Dietary Management. Nutrients. 2015 Sep 18;7(9):8020-35.10.3390/nu7095380Search in Google Scholar PubMed PubMed Central
52. Nolan-Clark D., Tapsell LC., Hu R., Han DY., Ferguson LR.: Effects of dairy products on crohn’s disease symptoms are influenced by fat content and disease location but not lactose content or disease activity status in a New Zealand population. J Am Diet Assoc. 2011 Aug;111(8):1165-72.10.1016/j.jada.2011.05.004Search in Google Scholar PubMed
53. von Tirpitz C., Kohn C., Steinkamp M., Geerling I., Maier V., Moller P., et all: Lactose intolerance in active Crohn’s disease: clinical value of duodenal lactase analysis. J Clin Gastroenterol. 2002 Jan;34(1):49-53.10.1097/00004836-200201000-00009Search in Google Scholar PubMed
54. Sugihara K., Masuda M., Nakao M., Abuduli M., Imi Y., Oda N., et all: Dietary phosphate exacerbates intestinal inflammation in experimental colitis. J Clin Biochem Nutr. 2017 Sep;61(2):91-99.10.3164/jcbn.16-117Search in Google Scholar PubMed PubMed Central
55. Richman E., Rhodes JM.: Review article: evidence-based dietary advice for patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Nov;38(10):1156-71.10.1111/apt.12500Search in Google Scholar PubMed
56. Butler M., Boyle JJ., Powell JJ., Playford RJ., Ghosh S.: Dietary microparticles implicated in Crohn’s disease can impair macrophage phagocytic activity and act as adjuvants in the presence of bacterial stimuli. Inflamm Res. 2007 Sep;56(9):353-61.10.1007/s00011-007-7068-4Search in Google Scholar PubMed
57. Viennois E., Merlin D., Gewirtz AT., Chassaing B.: Dietary Emulsifier-Induced Low-Grade Inflammation Promotes Colon Carcinogenesis. Cancer Res. 2017 Jan 1;77(1):27-40.10.1158/0008-5472.CAN-16-1359Search in Google Scholar PubMed PubMed Central
58. Tobacman JK.: Review of harmful gastrointestinal effects of carrageenan in animal experiments. Environ Health Perspect. 2001 Oct; 109(10): 983-994.10.1289/ehp.01109983Search in Google Scholar PubMed PubMed Central
59. Martino JV., Van Limbergen J., Cahill LE.: The Role of Carrageenan and Carboxymethylcellulose in the Development of Intestinal Inflammation. Front Pediatr. 2017 May 1;5:96.10.3389/fped.2017.00096Search in Google Scholar PubMed PubMed Central
60. Wei W., Feng W., Xin G., Tingting N., Zhanghe Z., Haimin C., Xiaojun Y.: Enhanced effect of κ-carrageenan on TNBS-induced inflammation in mice. Int Immunopharmacol. 2016 Oct;39:218-228.10.1016/j.intimp.2016.07.031Search in Google Scholar PubMed
61. Swidsinski A., Ung V., Sydora BC., Loening-Baucke V., Doerffel Y., Verstraelen H., Fedorak RN.: Bacterial overgrowth and inflammation of small intestine after carboxymethylcellulose ingestion in genetically susceptible mice. Inflamm Bowel Dis. 2009 Mar;15(3):359-64.10.1002/ibd.20763Search in Google Scholar PubMed
62. Laudisi F., Di Fusco D., Dinallo V., Stolfi C., Di Grazia A., Marafini I., et all: The Food Additive Maltodextrin Promotes Endoplasmic Reticulum Stress-Driven Mucus Depletion and Exacerbates Intestinal Inflammation. Cell Mol Gastroenterol Hepatol. 2018.10.1016/j.jcmgh.2018.09.002Search in Google Scholar PubMed PubMed Central
63. Byrne G., Rosenfeld G., Leung Y., Qian H., Raudzus J., Nunez C., Bressler B.: Prevalence of Anxiety and Depression in Patients with Inflammatory Bowel Disease. Can J Gastroenterol Hepatol. 2017;2017:649672710.1155/2017/6496727Search in Google Scholar PubMed PubMed Central
64. Levy RL., van Tilburg MA., Langer SL., Romano JM., Walker LS., Mancl LA., et all: Effects of a Cognitive Behavioral Therapy Intervention Trial to Improve Disease Outcomes in Children with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Sep;22(9):2134-48.10.1097/MIB.0000000000000881Search in Google Scholar PubMed PubMed Central
65. Breit S., Kupferberg A., Rogler G., Hasler G.: Vagus Nerve as Modulator of the Brain-Gut Axis in Psychiatric and Inflammatory Disorders. Front Psychiatry. 2018; 9: 44.10.3389/fpsyt.2018.00044Search in Google Scholar PubMed PubMed Central
66. Raison CL., Capuron L., Miller AH.: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006 Jan;27(1):24-31.10.1016/j.it.2005.11.006Search in Google Scholar PubMed PubMed Central
67. Fuller-Thomson E., Lateef R., Sulman J.: Robust Association Between Inflammatory Bowel Disease and Generalized Anxiety Disorder: Findings from a Nationally Representative Canadian Study. Inflamm Bowel Dis. 2015 Oct;21(10):2341-8.10.1097/MIB.0000000000000518Search in Google Scholar PubMed
68. Nowaczyk M., Żołądek M., Philavong P., Linke K., Łykowska- Szuber L., Krela-Kaźmierczak I.: Zaćma jako powikłanie przewlekłej steroidoterapii stosowanej w leczeniu choroby Leśniowskiego-Crohna. Forum Medycyny Rodzinnej, 2016;10(6):314-318.Search in Google Scholar
69. Bartnik W.: Wytyczne postępowania w nieswoistych chorobach zapalnych jelit. Przegląd Gastroenterologiczny, 2007;2(5):215-229.Search in Google Scholar
70. Manganelli C., Turco S., Balestrazzi E. Ophthalmological aspects of IBD. Eur. Rev. Med. Pharmacol. Sci. 2009; 13: 11-13.Search in Google Scholar PubMed
71. Philavong P., Żołądek M., Nowaczyk M., Linke K., Łykowska- Szuber L., Krela-Kaźmierczak I: Osteoporoza posteroidowa w chorobie Leśniowskiego-Crohna. Gastroenterologia Kliniczna, 2016;8(1):36-41.Search in Google Scholar
72. Chao CY., Battat R., Khoury A., Sebastiani G., Bessissow T.: Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article. World J Gastroenterol, 2016;22(34):7727-7734.10.3748/wjg.v22.i34.7727Search in Google Scholar PubMed PubMed Central
73. Dejian L., Chao L., Chaohui Y.: High incidence of non-alcoholic fatty liver disease in patients with Crohn’s disease but nor ulcerative colitis. Int J Clin Exp Pathol, 2017;10(10):10633=10639.Search in Google Scholar
© 2019 Justyna Kikut, et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
